ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of ...
Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of ...
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of ...
ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene ...
GlobalData on MSN
Acerand reports first-in-human trial results for ACE-106 therapy
ACE-106 demonstrated notable anti-tumour activity across different tumour types.
Artificial intelligence (AI) is emerging as a powerful force in breast cancer research, but the future of personalized care ...
Acerand Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, ...
Bayer (BAYRY) is running an Australian study called “Treatment Patterns and Characteristics of Patients Receiving Androgen Receptor Pathway Inhibitors in a Real-world Setting in Australia: A ...
Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous Clascoterone treatment continued to gain hair through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results